CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Dulaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03315780
NCT03315780Phase 4Completed

A Phase 4 Study to Evaluate Glucodynamic Effects of Dulaglutide in Japanese Patients With Type 2 Diabetes Mellitus

Eli Lilly and Company·interventional·Posted Oct 20, 2017·Updated Sep 16, 2019

In Brief

A Phase 4 clinical trial evaluating Dulaglutide and Placebo for Type 2 Diabetes. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the glucodynamic effects of dulaglutide in Japanese participants with type 2 diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedOct 20, 2017
Enrollment StartOct 28, 2017
Primary CompletionFeb 28, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.7 years ago

Interventions

Dulaglutidedrug

Administered SC

Placebodrug

Administered SC